3-D Matrix (7777) AI Stock Analysis

• Market Cap: $23.16B
• Dividend Yield: N/A
• Average Volume (3M): 1.66M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 78.18%
• EPS Growth: 35.77%
• Country: JP
• Employees: 106
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Devices
• EPS (TTM): -9.57
• Shares Outstanding: 110,293,400
• 10 Day Avg. Volume: 2,855,330
• 30 Day Avg. Volume: 1,656,656
• PEG Ratio: -0.42
• Price to Book (P/B): 18.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ¥136.00 ▼(-35.24%Downside)

3-D Matrix's stock score reflects a mixed picture. The company has achieved strong revenue growth, but its high leverage and ongoing profitability challenges pose significant risks. Technical indicators are favorable, suggesting some positive momentum, but negative valuation metrics highlight concerns about the stock's current price relative to its earnings potential.

3-D Matrix Business Overview & Revenue Model

Company Description

3-D Matrix (7777) is a biotechnology company that specializes in developing innovative regenerative medicine products. The company focuses on creating self-assembling peptide technologies that are used in various medical applications, including tissue regeneration, drug delivery, and wound healing. With a commitment to advancing healthcare solutions, 3-D Matrix operates primarily in the biotechnology and pharmaceuticals sectors.

How the Company Makes Money

3-D Matrix generates revenue through the development and commercialization of its proprietary self-assembling peptide technology. The company earns money by licensing its technology to pharmaceutical and medical device companies, as well as through direct sales of its products used in healthcare settings. Key revenue streams include partnerships and collaborations with other biotech firms, which enable the company to leverage its technology across different therapeutic and medical areas. Additionally, 3-D Matrix may receive milestone payments and royalties from its licensing agreements, contributing to its overall earnings.

3-D Matrix Financial Statement Overview

Summary

3-D Matrix shows strong revenue growth but faces significant challenges with profitability and cash flow. The company has high leverage with a debt-to-equity ratio of 11.82 and a low equity base, indicating financial risk.

Income Statement

3-D Matrix has shown a strong revenue growth rate of 98.32% from 2023 to 2024, indicating positive momentum. However, the company remains unprofitable with a negative EBIT margin and net profit margin due to significant operating losses.

Balance Sheet

The company has a very high debt-to-equity ratio of 11.82, indicating high leverage and risk. The equity ratio is low at 6.0%, suggesting limited equity buffer, which might pose financial risk.

Cash Flow

While there is an improvement in operating cash flow, the free cash flow remains negative, reflecting ongoing cash burn. The operating cash flow to net income ratio is negative, highlighting cash flow challenges.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
6.03B	4.59B	2.31B	1.51B	1.02B	672.42M
	Gross Profit
4.19B	3.09B	1.29B	661.01M	304.91M	111.98M
	EBIT
-1.43B	-2.12B	-3.16B	-2.74B	-2.65B	-2.54B
	EBITDA
113.96M	59.13M	715.00M	843.00M	638.00M	-559.00M
	Net Income Common Stockholders
-921.91M	-255.50M	-2.45B	-1.89B	-2.01B	-3.10B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.07B	1.36B	1.17B	2.85B	1.14B	1.06B
	Total Assets
6.70B	5.89B	5.83B	5.61B	3.51B	3.12B
	Total Debt
3.85B	4.17B	4.37B	3.67B	1.46B	1.80B
	Net Debt
1.79B	2.81B	3.20B	816.45M	319.80M	741.96M
	Total Liabilities
4.89B	5.53B	5.30B	4.15B	1.85B	2.64B
	Stockholders Equity
1.81B	353.31M	524.77M	1.46B	1.66B	473.02M
Cash Flow		Free Cash Flow
0.00	-1.90B	-4.60B	-2.92B	-3.28B	-2.21B
	Operating Cash Flow
0.00	-1.90B	-4.59B	-2.90B	-3.25B	-2.19B
	Investing Cash Flow
0.00	-29.76M	-81.50M	-79.86M	-160.32M	-112.79M
	Financing Cash Flow
0.00	2.06B	2.96B	4.66B	3.46B	1.57B

3-D Matrix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 210.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7777, the sentiment is Positive. The current price of 210 is above the 20-day moving average (MA) of 147.20, above the 50-day MA of 132.90, and above the 200-day MA of 131.66, indicating a bullish trend. The MACD of 11.19 indicates Negative momentum. The RSI at 88.99 is Negative, neither overbought nor oversold. The STOCH value of 87.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7777.

3-D Matrix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7963	81 Outperform	¥8.58B	10.25		2.04%	11.24%	53.32%
5187	78 Outperform	¥8.64B	8.41		4.21%	4.59%	1130.01%
7792	77 Outperform	¥12.07B	9.54		2.25%	13.54%	78.47%
6678	74 Outperform	¥15.81B	12.79		3.67%	5.92%	8.59%
7600	55 Neutral	¥14.41B	10.23		2.74%	8.35%	-136.31%
7777	54 Neutral	$23.16B	―	-184.59%	―	78.18%	35.77%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%